Novartis' radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectations - FiercePharma
[unable to retrieve full-text content] Novartis' radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectations FiercePharma Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer Clinical Oncology News FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer Cancer Network FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer The ASCO Post Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer Novartis View Full Coverage on Google News